创新药迎来 戴维斯双击

证券市场周刊
Yesterday

在政策、人才、资本等多重利好因素的推动下,中国创新药行业进入了成长飞轮的正向循环,迎来系统性投资机会。中国创新药行业正迎来“戴维斯双击”。6月9日,A股及港股市场医药生物板块全线走强,创新药方向领涨,板块指数放量大涨逾4%,创历史新高,多只创新药股价冲击涨停。港股医药股也跟随大涨,恒生创新药指数亦创历史新高,中华香港生物科技指数、港股通医疗保健指数、恒生医疗保健指数纷纷创2年来新高。在政策、人才、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10